Research outline - Molecular Pharmacology and Pathology Program (MPP)

Within: Bosch Institute, Discipline of Pathology

On this page:

Overview of research program

Iron is essential for life and growth. While it is well known that iron deficiency can lead to anaemia it is generally not appreciated that iron is critical for the growth of all cells, particularly cancer cells. The Iron Metabolism and Chelation Program is concerned with understanding the basic processes of how tumour cells utilise and transport iron. This knowledge will lead to the development of therapies that can selectively starve tumour cells of iron and inhibit their growth. In addition, we are studying the mechanisms involved in iron loading in the inherited diseases I2-thalassaemia and Friedreich's ataxia.

Major funding sources

  • NHMRC Project Grant - Development of Iron Complexes for the Treatment of Friedreich?s Ataxia & the Role of Frataxin in Iron Metabolism. Richardson D, Suryo Rahmanto Y, Ponka P. $595,048
  • NHMRC Project Grant - Pharmacological Targeting via AKT, PTEN, and TGF-beta Pathway Integration using Novel Therapeutics
    Richardson D, Assinder S, Dong Q. $611,875
  • ARC Discovery Project - The Effect of Nitrogen Monoxide on Intracellular Iron Metabolism. Richardson D. $540,000
  • NHMRC Project Grant - Alpha-2-macroglobulin and the transport and uptake of the hormone, hepcidin. Richardson D, Suryo Rahmanto Y, Kuchel P. $514,500 over 3 years
  • NHMRC Development Grants - Toxicological and pre-clinical assessment of the anti-cancer compound Bp4eT. Richardson D, Lovejoy D, Mills J. $195,000
  • NHMRC Project Grants - Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class. Richardson D, Kalinowski D, Lovejoy D, Bernhardt P. $563,500
  • NHMRC Project Grants - The Role of Melanoma Tumour Antigen p97 (Melanotransferrin) in Melanoma Tumourenesis. Richardson D, Suryo Rahmanto Y. $541,250
  • NHMRC Research Fellowship. Richardson D. $766,250
  • NHMRC Project Grant - Development of Iron Chelators for the Treatment of Friedreichs Ataxia and the Role of Frataxin in Mitochondrial Iron Metabolism. Richardson D, Davies M. $528,250
  • Friedreich's Ataxia Research Alliance (USA) Research Support - Establishment of a Breeding Colony of the NSE. Richardson D. $50,000
  • Friedreich's Ataxia Research Alliance (USA) Research Support - Understanding the Pathogenesis of Friedreich's Ataxia to Aid in the Development of New Therapeutic Regimes. Richardson D. $50,000
  • Muscular Dystrophy Association (USA) Research Support - The role of iron in Friedreich's Ataxia and the Use of Iron Chelation Therapy. Richardson D. $542,379
  • NHMRC Project Grant - Lipocalin 2 in host defence of the central nervous system. Campbell I, King N, Richardson D. $549,500
  • NHMRC - Research Fellowship. Richardson D. $651,250

Selected publications

  • Jansson, P, Hawkins, C, Lovejoy, D, Richardson, D. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study. Journal of inorganic biochemistry. 2010; 104:1224-8
  • Merlot, A, Pantarat, N, Lovejoy, D, Kalinowski, D, Richardson, D. Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular pharmacology. 2010; 78:675-84
  • Jansson, P, Sharpe, P, Bernhardt, P, Richardson, D. Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity. Journal of medicinal chemistry. 2010; 53:5759-69